The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

VOLUME 53 , ISSUE 3 ( July-September, 2011 ) > List of Articles

Original Article

Anti-Oxidant Treatment in Obstructive Sleep Apnoea Syndrome

K. Sadasivam, K. Patial, V.K. Vijayan, K. Ravi

Keywords : Anti-oxidant, N-acetylcysteine, Oxidative stress, Sleep apnoea

Citation Information : Sadasivam K, Patial K, Vijayan V, Ravi K. Anti-Oxidant Treatment in Obstructive Sleep Apnoea Syndrome. Indian J Chest Dis Allied Sci 2011; 53 (3):153-172.

DOI: 10.5005/ijcdas-53-3-153

License: CC BY-NC 4.0

Published Online: 10-06-2022

Copyright Statement:  Copyright © 2011; The Author(s).


Abstract

Purpose. To investigate whether oral intake of N-acetylcysteine (NAC) is a treatment option in patients with obstructive sleep apnoea syndrome (OSAS). Methods. Twenty patients with OSAS were enrolled in the study. After polysomnography (PSG), they were randomly assigned to receive a placebo (n=10) and NAC (n=10). A repeat PSG was done after the treatment period of 30 days. Fasting venous samples were collected for various biochemical analysis. Results. In the patients of NAC group, compared to their baseline values, slow wave sleep as sleep percent time (27.9±2.7 vs 42.3±4.2; p<0.01) and sleep efficiency (90.8±1.3 vs 94.4±1.5; p<0.05) improved considerably. The apnoea-hypopnoea index (61.2±8.5 vs 43.1±8.6; p<0.05), apnoea related arousals (22.2±7.6 vs 11.6±4.7; p<0.05), longest apnoeic episode duration (seconds) (54.9±7.1 vs 37.8±5.6; p<0.01), oxygen desaturation events per hour (51.8±7.7 vs 37±7.8; p<0.01) and epworth sleepiness score (16.6±0.8 vs 9.2±0.9; p<0.001) decreased significantly. The relative snore time (%) (10.2±2.9 vs 4.9±1.9; p<0.01), number of snore episodes (63.8±23.9 vs 28.2±9.9; p<0.05) and duration of longest snore episode (min) (2.5±0.7 vs 0.6±0.1; p<0.05) also decreased significantly. Such responses were not evident in the placebo group. N-acetylcysteine produced significant decrease in lipid peroxidation and increase in total reduced glutathione. Conclusions. Oral NAC administration appears to have a therapeutic potential in the treatment of OSAS. It is proposed that long-term treatment with NAC in patients with OSAS may reduce their dependency on continuous positive airway pressure therapy.


PDF Share
  1. Hatipoglu U, Rubinstein I. Inflammation and obstructive sleep apnoea syndrome: how many ways do I look at these? Chest 2004;126:1-2.
  2. Israel SA, Kripke DF, Klauber MR, Mason WJ, Fell R, Kaplan O. Sleep-disordered breathing in communitydwelling elderly. Sleep 1991;14:486-95.
  3. Stepnowsky C Jr, Moore PJ. Nasal CPAP treatment for obstructive sleep apnoea: developing a new perspective on dosing strategies and compliance. J Psychosom Res 2003; 54:599-605.
  4. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens 2000;18:655-73.
  5. Weiss JW, Launois SH, Anand A, Garpestad E. Cardiovascular morbidity in obstructive sleep apnoea. Prog Cardiovasc Dis 1999:41:367-76.
  6. Yamauchi M, Nakano H, Maekawa J, Okamoto Y, Ohnishi Y, Suzuki T. Oxidative stress in obstructive sleep apnoea. Chest 2005;127:1674-9.
  7. Singh TD, Patial K, Vijayan VK, Ravi K. Oxidative stress and obstructive sleep apnoea syndrome. Indian J Chest Dis Allied Sci 2009;51:217-24.
  8. Halliwell B. Anti-oxidants in human health and disease. Annu Rev Nutr 1996;16:33-50.
  9. Kamboj SS, Chopra K, Sandhir R. Neuroprotective effect of N-acetylcysteine in the development of diabetic encephalopathy in streptozotocin-induced diabetes. Metab Brain Dis 2008;23:427-43.
  10. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991;14: 540-5.
  11. Rechtschaffen A, Kales A. A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects. Los Angeles: Brain Information Service/Brain Research Institute, University of California, 1968.
  12. Lee-Chiong T, Brown WD. Polysomnography II. Respir Care Clin North Am 2006;12:15-16.
  13. Iber C, Ancoli-Israel S, Chesson A, et al. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications; 1st edition. Westchester: American Academy of Sleep Medicine, 2007.
  14. Philips P, Kryger M. Management of obstructive sleep apnoea-hypopnea syndrome: overview. In: Kryger M, editor Principles and Practice of Sleep Medicine. Philadelphia: Elsevier 2006;1109-21.
  15. Griffith OW. Determination of glutathione and glutathione reductase and 2-vinyl pyridine. Ann Biochem 1980;106:207-12.
  16. Yagi K. Assay for blood plasma or serum. Methods Enzymol 1984;105:328-31.
  17. Dousset J, Trouilh M, Foglietti M. Plasma malonaldehyde levels during myocardial infarction. Clin Chim Acta 1983;129:319-22.
  18. Mastarakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic pituitary adrenal axis in humans. J Clin Endocrinol Metab 1993;77:1690-4.
  19. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab 1997;82:1313-6.
  20. McCord JM. The evolution of free radicals and oxidative stress. Am J Med 2000;108:652-9.
  21. Veasey SC, Davis CW, Fenik P, Zhan G, Hsu Y-J, Pratico D, et al. Long-term intermittent hypoxia in mice: protracted hypersomnolence with oxidative injury to sleep/wake brain regions. Sleep 2004;27:194-20.
  22. Hatipodlu U, Rubinstein I. Inflammation and obstructive sleep apnoea syndrome pathogenesis: a working hypothesis. Respiration 2003;70:665-71.
  23. Veasey SC, Zhan G, Fenik P, Pratico D. Long term intermittent hypoxia reduced excitatory hypoglossal nerve output. Am J Respir Crit Care Med 2004;170:665-72.
  24. Dunleavy M, Bradford A, O'Halloran KD. Oxidative stress impairs upper airway muscle endurance in a animal model of sleep disordered breathing. Adv Exp Med Bio 2008;605:458-62.
  25. Skelly RJ, Bradford A, Jones JFX, O'Halloran KD. Superoxide scavengers improve rat pharyngeal dilator muscle performance. Am J Respir Cell Mol Biol 2010; 42:725-31.
  26. Smith MA, Reid MB. Redox modulation of contractile function in respiratory and limb skeletal muscle. Respir Physiol Neurobi 2006;151:229-41.
  27. Reid MB. Redox modulation of skeletal muscle contraction by reactive oxygen and nitric oxide. In: Hargreaves M, Thompson M, editors Biochemistry of Exercise X. Champaign, IL: Human Kinetics; 1999: pp 155-66.
  28. Kannan R, Kuhlenkamp JF, Jeandidier E, Trinh H, Ookhtens M, Kaplowitz N. Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat. J Clin Invest 1990;85:2009-13.
  29. Deegan PC, McNicholas WT. Pathophysiology of Obstructive Sleep Apnoea. Eur Respir J 1995;8:1161-78.
  30. O'Donnell CP, Schwartz AR, Smith PL. Upper airway collapsibility: the importance of gender and adiposity. Am J Respir Crit Care Med 2000;162:1606-7.
  31. Gozal D, Leila KG. Cardiovascular Morbidity in obstructive sleep apnoea. Am J Respir Crit Care Med 2008;177:369-75.
  32. Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnoea patients. Am J Respir Crit Care Med 2002;165:934-9.
  33. Christou K, Moulas AN, Pastaka C. Anti-oxidant capacity in obstructive sleep apnoea patients. Sleep Med 2003;4:225-8.
  34. Ruffmann R, Wendel A. GSH rescue by N-acetylcysteine. Klin Wochenschr 1991;69:857-62.
  35. Scholz RW, Graham KS, Gumpricht E, Reddy CC. Mechanism of interaction of vitamin E and glutathione in the protection against membrane lipid peroxidation. Ann NY Acad Sci 1989:570:514-7.
  36. Hughes RE. Reduction of dehydroascorbic acid by animal tissues. Nature 1964:203:1068-9.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.